Literature DB >> 15073267

Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model.

Aren van Waarde1, David C P Cobben, Albert J H Suurmeijer, Bram Maas, Willem Vaalburg, Erik F J de Vries, Pieter L Jager, Harald J Hoekstra, Philip H Elsinga.   

Abstract

UNLABELLED: Increased glucose metabolism of inflammatory tissues is the main source of false-positive (18)F-FDG PET findings in oncology. It has been suggested that radiolabeled nucleosides might be more tumor specific.
METHODS: To test this hypothesis, we compared the biodistribution of 3'-deoxy-3'-(18)F-fluorothymidine (FLT) and (18)F-FDG in Wistar rats that bore tumors (C6 rat glioma in the right shoulder) and also had sterile inflammation in the left calf muscle (induced by injection of 0.1 mL of turpentine). Twenty-four hours after turpentine injection, the rats received an intravenous bolus (30 MBq) of either (18)F-FLT (n = 5) or (18)F-FDG (n = 5). Pretreatment of the animals with thymidine phosphorylase (>1,000 U/kg, intravenously) before injection of (18)F-FLT proved to be necessary to reduce the serum levels of endogenous thymidine and achieve satisfactory tumor uptake of radioactivity.
RESULTS: Tumor-to-muscle ratios of (18)F-FDG at 2 h after injection (13.2 +/- 3.0) were higher than those of (18)F-FLT (3.8 +/- 1.3). (18)F-FDG showed high physiologic uptake in brain and heart, whereas (18)F-FLT was avidly taken up by bone marrow. (18)F-FDG accumulated in the inflamed muscle, with 4.8 +/- 1.2 times higher uptake in the affected thigh than in the contralateral healthy thigh, in contrast to (18)F-FLT, for which this ratio was not significantly different from unity (1.3 +/- 0.4).
CONCLUSION: In (18)F-FDG PET images, both tumor and inflammation were visible, but (18)F-FLT PET showed only the tumor. Thus, the hypothesis that (18)F-FLT has a higher tumor specificity was confirmed in our animal model.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15073267

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  94 in total

1.  Positron emission tomography with [(18)F]-3'-deoxy-3'fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study.

Authors:  Farrokh Dehdashti; Perry W Grigsby; Robert J Myerson; Ilke Nalbantoglu; Changqing Ma; Barry A Siegel
Journal:  Mol Imaging Biol       Date:  2013-02       Impact factor: 3.488

2.  Investigation of the pharmacokinetics of 3'-deoxy-3'-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer.

Authors:  Yusuf Menda; Laura L Boles Ponto; Kenneth J Dornfeld; Timothy J Tewson; G Leonard Watkins; Anjali K Gupta; Carryn Anderson; Sarah McGuire; Michael K Schultz; John J Sunderland; Michael M Graham; John M Buatti
Journal:  Nucl Med Biol       Date:  2010-05       Impact factor: 2.408

Review 3.  [18F]FLT-PET in oncology: current status and opportunities.

Authors:  Lukas B Been; Albert J H Suurmeijer; David C P Cobben; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12       Impact factor: 9.236

4.  Molecular imaging in animal models of disease--every little detail counts!

Authors:  Farrokh Pakzad; Peter J Ell; Ignasi Carrió
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08       Impact factor: 9.236

5.  [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung.

Authors:  Marcelo Mamede; Tatsuya Higashi; Masanori Kitaichi; Koichi Ishizu; Takayoshi Ishimori; Yuji Nakamoto; Kazuhiro Yanagihara; Mio Li; Fumihiro Tanaka; Hiromi Wada; Toshiaki Manabe; Tsuneo Saga
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

6.  The Medical Case for a Positron Emission Tomography and X-ray Computed Tomography Combined Service in Oman.

Authors:  Naima K Al-Bulushi; Dale Bailey; Giuliano Mariani
Journal:  Sultan Qaboos Univ Med J       Date:  2013-11-08

7.  Detection of pulmonary metastases with the novel radiolabeled molecular probe, (99m)Tc-RRL.

Authors:  Ning Yao; Ping Yan; Rong-Fu Wang; Chun-Li Zhang; Chao Ma; Xue-Qi Chen; Qian Zhao; Pan Hao
Journal:  Int J Clin Exp Med       Date:  2015-02-15

8.  Extensive FDG uptake and its modification with corticosteroid in a granuloma rat model: an experimental study for differentiating granuloma from tumors.

Authors:  Songji Zhao; Yuji Kuge; Masashi Kohanawa; Toshiyuki Takahashi; Hidekazu Kawashima; Takashi Temma; Toshiki Takei; Yan Zhao; Koh-ichi Seki; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-01       Impact factor: 9.236

9.  Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101.

Authors:  Thomas S C Ng; David Wert; Hargun Sohi; Daniel Procissi; David Colcher; Andrew A Raubitschek; Russell E Jacobs
Journal:  Clin Cancer Res       Date:  2013-03-26       Impact factor: 12.531

10.  Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.

Authors:  David M Atkinson; Michelle J Clarke; Ann C Mladek; Brett L Carlson; David P Trump; Mark S Jacobson; Brad J Kemp; Val J Lowe; Jann N Sarkaria
Journal:  Head Neck       Date:  2008-06       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.